Anales de la RANM

95 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 CONTRIBUTION OF 18F-FDG PET/CT IN OCCULT BREAST CARCINOMA Valhondo-Rama, et al. An RANM. 2021;138(01): 92 - 95 breast observation does not adversely influence survival, whereas others report a local recurrence rate of 15.4–63.6% in those cases.(6–8) Yang et al(10) support that OBC might have an excellent response to neoadjuvant chemotherapy achieving pathological complete response, with better survival for these patients. We consider that further studies are required to approve this option taking into account the psychological impact too. In conclusion, findings on 18 F-FDG PET/CT can determine a better management. We strongly support its utility for a proper diagnosis, staging and follow-up of patients with OBC. It indeed should be indicated when the primary tumour remains undetected by other diagnostic techniques, specially today when there are new PET/CT equipments available with improved sensitivity and specificity in breast diseases. On the other hand, surgical treatment with breast preservation plus RT instead of mastectomy should be considered in all cases of OBC. Multidisciplinary approach is crucial to reach an optimal management and prognosis for these patients. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. 1. Soundararajan R, Naswa N, Karunanithi S, Walia R, Kumar R, Bal C. Occult breast pri- mary malignancy presenting as isolated axil- lary lymph node metastasis - early detection of primary site by 18F-FDG PET/CT. Nucl Med Rev. 2016;19:B5–7. 2. Liu M, Liu B, Song Y, Ding L, Dong L. FDG PET/CT reveals the primary tumor in a patient with occult breast carcinoma unde- tected by other modalities. Clin Nucl Med. 2014;39(8):755–757. 3. Takabatake D, Taira N, Aogi K, et al. Two cases of occult breast cancer in which PET- CT was helpful in identifying primary tumors. Breast Cancer. 2008;15(2):181–184. 4. Banzo J, Ubieto MA, González C, et al. Pap- illary thyroid carcinoma synchronous with breast cancer: An incidental finding in an 18F- FDG PET-CT study carried out in a search for occult breast cancer. Rev Esp Med Nucl Imag Mol. 2012;31(4):213–215. DOI: 10.1016/j. remnie.2012.06.013 5. Park JS, Lee AY, Bae SG, Lee SM. Hyper- metabolic axillary mass on 18 f FDG PET/CT: Breast cancer arising from accessory breast tis- sue. Nucl Med Mol Imaging. 2010;44(4):300– 303. 6. Ge LP, Liu XY, Xiao Y, et al. Clinicopatho- logical characteristics and treatment out- comes of occult breast cancer: A SEER population-based study. Cancer Manag Res. 2018;10:4381–4391. 7. Johnson HM, Irish W, Vohra NA, Wong JH. The effect of local therapy on breast cancer- specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): a population analysis. Breast Cancer Res Treat. 2019;177(1):155 ‐ 164. DOI: 10.1007/s10549- 019-05285-x 8. Terada M, Adachi Y, Sawaki M, et al. Occult breast cancer may originate from ectopic breast tissue present in axillary lymph nodes. Breast Cancer Res Treat. 2018;172(1):1 ‐ 7. DOI: 10.1007/s10549-018-4898-4 9. Uribe A, Berrios C, Yi Li Y. Cáncer en mama axilar: Revisión de la literatura a propósi- to de un caso. Rev Chil Obstet Ginecol. 2017;82(4):416–423. DOI: 10.4067/s0717- 75262017000400416  10. Yang H, Li L, Zhang M, Zhang S, Xu S, Ma X. Application of neoadjuvant chemotherapy in occult breast cancer: Five case reports. Medi- cine (Baltimore). 2017;96(40):e8200. DOI: 10.1097/MD.0000000000008200. CONFLICT OF INTEREST The authors declare that they have no conflicts of interest. BIBLIOGRAPHY FUNDING Si desea citar nuestro artículo: Valhondo-Rama R, Brenes Sánchez JM, Wakfie-Corieh CG, Rodríguez Rey C, Herrera De la Muela M, Carreras Delgado JL. Contribution of Whole- Body Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography. An RANM. 2021;138(01): 92– 95. DOI: 10.32440/ar.2021.138.01. rev10